SIVEXTRO INJECTION Rx
Generic Name and Formulations:
Tedizolid phosphate 200mg; lyophilized pwd for IV infusion after reconstitution; preservative-free.
Merck & Co., Inc.
Indications for SIVEXTRO INJECTION:
Susceptible acute bacterial skin and skin structure infections (ABSSSI).
≥18yrs: Infuse 200mg once daily over 1 hour for 6 days. Switching from IV to oral: no dose adjustment necessary.
<18yrs: not established.
Not adequately evaluated in patients with neutropenia (ANC <1000 cells/mm3); consider alternate therapies. Risk of C. difficile-associated diarrhea; discontinue if suspected or confirmed. Pregnancy (Cat.C). Nursing mothers.
Tabs: May potentiate oral BCRP substrates; consider interrupting co-administered substrates esp. those with narrow therapeutic index (eg, methotrexate, topotecan); monitor if coadministration (including rosuvastatin) is necessary.
Nausea, headache, diarrhea, vomiting, dizziness.
Tabs—6 (blister pack), 30; single-use vials—10
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Behavioral Weight Loss Interventions May Prevent Obesity
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Executive Function Predicts T1D Management Into Emerging Adulthood
- Intensive Blood Pressure Therapy Lowers Cardiovascular Risk in Diabetes
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age
- LVAD in Heart Failure Linked to Improved Glycemic Control
- Fundamental Institutional Change Is Needed to Eliminate Sexual Harassment
- Gestational Diabetes Tied to Subsequent Glucose Disorders
- Association Health Plans Can Help Small Businesses Offer Coverage